Hoxworth Furthers Cooperation with Biolog-id to Support New FDA Guidance
22.12.2020 10:43:00 EET | Business Wire | Press release
Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today that University of Cincinnati’s Hoxworth Blood Center is expanding its deployment of Biolog-id’s advanced solutions to support the efficient implementation of the FDA’s new platelet guidelines.
“By widening the scope of the Biolog-id solution we are able to extend our digital visibility to the manufacturing environment of our blood products,” said Judith Gonzalez, Division Director of Laboratories at Hoxworth Blood Center. “We can leverage our access to both real-time and retrospective data to effectively manage multiple manufacturing strategies for platelets, as part of the new FDA guidance.”
“The close cooperation with the Hoxworth team allowed us to tailor our technology to the specific challenges and opportunities associated with the new guidance,” said Amit Mayer, VP Innovation & Analytics at Biolog-id LLC. “By identifying the right data to collect, and the right ways to present it, we were able to quickly develop a set of tools that have a meaningful impact for Hoxworth, as well as other blood centers.”
“The Biolog-id solution is a unique combination of hardware, software, consumables, and data. This platform supports a higher level of service for the hospitals we serve and their patients in need,” said Dr. Jose Cancelas, Director of Hoxworth Blood Center. “The ability of the Biolog-id technology to generate value throughout the lifecycle of blood products makes it a very compelling platform for blood centers and their hospital customers.”
The Biolog-id technology is compatible across multiple systems, software, and hardware. That flexibility of the Biolog-id platform, coupled with a customer-centric innovation focus, facilitates the development of dedicated tools that address the changing conditions in the industry. With an expanding customer base, in the US and world-wide, this combination also drives the ability to efficiently tailor Biolog-id’s solution to the unique needs of both blood centers and hospital blood banks, driving our ability to effectively scale.
About Biolog-id
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products. Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds.
Company URL: www.biolog-id.com
Hoxworth Blood Center/University of Cincinnati
Hoxworth Blood Center, an internationally-recognized leader in transfusion medicine, was founded in 1938 and is the second oldest blood bank in the country. Hoxworth serves more than 30 area hospitals and medical centers and collects more than 100,000 units of blood products to help save the lives of patients in area hospitals.
Company URL: https://hoxworth.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005850/en/
Contact information
Amit Mayer, amit.mayer@biolog-id.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 01:05:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs, including the Phase 3 KRAS G12D and TGFβR2×PD-1 studies already underway.” Details on rapid oral presentations at ESMO include: INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Monotherapy or in Combination with Cetuximab (Cetux) in Patients (pts) with Advanced/Metastatic Colorectal Cancer (CRC) Session:
DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future18.10.2026 21:35:00 EEST | Press release
The Digital Cooperation Organization (DCO) launched the second edition of the Digital Prosperity Awards (DPA), opening applications and nominations for eligible public-sector, private-sector and civil-society digital solutions across Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261018682401/en/ DCO Launches Second Edition of Digital Prosperity Awards to Recognize Solutions Building the Digital Future (Photo: AETOSWire) The Awards recognize technology-driven solutions, initiatives and contributions delivering measurable socioeconomic impact, accelerating digital transformation and advancing an inclusive, sustainable and prosperous digital economy. The inaugural edition honored seven winners in February 2025. Ms. Deemah AlYahya, Secretary-General of the DCO, said: “A prosperous digital future is taking shape today through the vision, commitment and creativity of governments, innovators, organization
TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal16.10.2026 17:00:00 EEST | Press release
TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device. Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams: Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts. Developers pick a model and OS version, or let the cloud assign any available device. A live view of the device. The real device's screen opens in its own window on the developer's lapto
Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World16.10.2026 17:00:00 EEST | Press release
Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016490320/en/ Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World (Photo: AETOSWire) It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment. The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating oppor
METI and GX Acceleration Agency will hold GGX Finance Summit 202616.10.2026 16:00:00 EEST | Press release
On Monday, October 26th, the Ministry of Economy, Trade and Industry (METI) and GX Acceleration Agency will hold the GGX (Global GX) Finance Summit at Tokyo Prince Hotel and online. The Summit will advance discussions on transition finance, industry decarbonization, and the role of business and finance in driving decarbonization. It will also promote cooperation among government, industry, and the financial sector, and lead international rulemaking toward achieving both emission reductions and economic growth. Outline of GGX Finance Summit Date: October 26th, 2026 10:00 - 16:20 (JST, GMT+9:00) Venue: Tokyo Prince Hotel (Tokyo) (3-3-1 Shiba-Koen, Minato-ku, Tokyo 105-8560, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: GX Future Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation) Press Registration Please complete your registration by accessing the official
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
